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This subgroup analysis assessed the eﬃcacy of duloxetine in patients with chronic low back pain (CLBP) who did or did not use
concomitant nonsteroidal anti-inﬂammatory drugs (NSAIDs) or acetaminophen (APAP). Data were pooled from two 13-week
randomized trials in patients with CLBP who were stratiﬁed according to NSAID/APAP use at baseline: duloxetine NSAID/APAP
user (n = 137), placebo NSAID/APAP user (n = 82), duloxetine NSAID/APAP nonuser (n = 206), and placebo NSAID/APAP
nonuser (n = 156). NSAID/APAP users were those patients who took NSAID/APAP for at least 14 days per month during 3
months prior to study entry. An analysis of covariance model that included therapy, study, baseline NSAID/APAP use (yes/no),
andtherapy-by-NSAID/APAPsubgroupinteractionwasusedtoassesstheeﬃcacy.Thetreatment-by-NSAID/APAPuseinteraction
was not statistically signiﬁcant (P = 0.31) suggesting no substantial evidence of diﬀerential eﬃcacy for duloxetine over placebo on
pain reduction or improvement in physical function between concomitant NSAID/APAP users and non-users.
1.Introduction
Low back pain has a lifetime prevalence rate of 80% in the
United States and is one of the primary causes of disability
in individuals younger than 45 years of age [1, 2]. Low back
pain usually resolves spontaneously within a few days or
weeks, but for some individuals, this pain becomes chronic
[1]. Commonly prescribed medications for chronic low
back pain (CLBP) include nonsteroidal anti-inﬂammatory
drugs (NSAIDs), opioids, muscle relaxants, anticonvulsants,
and tricyclic antidepressants (TCAs) [3]. Over-the-counter
medications that are frequently used include acetaminophen
(APAP), aspirin, and certain NSAIDs [4]. However, there is
no clinical evidence to support the eﬃcacy of any of these
agents in CLBP [4, 5]. Furthermore, a number of these
treatmentsposesafetyrisksthatincludesedation,respiratory
depression and addiction (opioids), gastrointestinal bleeding
and ulcers, and cardiovascular events (NSAIDs) [6]. In
addition, antidepressants with serotonin reuptake inhibition
properties may increase the risk of bleeding events [7, 8],
either when taken alone or in combination with other drugs
that aﬀect coagulation, such as NSAIDs [9].
Duloxetine hydrochloride (hereafter referred to as dulox-
etine) is a potent serotonin and norepinephrine reuptake
inhibitor (SNRI) that has been approved by the United
States Food and Drug Administration for the management
of diabetic peripheral neuropathic pain, ﬁbromyalgia, and
chronic musculoskeletal pain (as established in studies in
CLBP and chronic pain due to osteoarthritis). It has also
beenapprovedforthetreatmentofmajordepressivedisorder
(MDD) and generalized anxiety disorder (GAD) [10].
In two 13-week trials of duloxetine versus placebo in pa-
tients with CLBP, one trial [11] reported signiﬁcantly great-
er pain reduction with duloxetine treatment at endpoint;2 Pain Research and Treatment
whereas the other reported signiﬁcant separation from
placeboatweeks3–11,butsuperioritywasnotdemonstrated
at endpoint [12]. Because these trials allowed concomitant
use of NSAIDs or APAP if patients used these analgesics
regularly prior to study entry, subgroup analyses were
conducted to assess whether or not concomitant use of the
allowed analgesics had an eﬀect on the eﬃcacy of duloxetine.
The results of the subgroup analyses were not signiﬁcant for
either trial, but were limited by sample size. To increase the
statistical power and to better understand the advantage of
duloxetine over placebo between the groups of patients who
concomitantly used these analgesics and those who did not,
we conducted a post hoc analysis of data pooled from these
two studies. The safety of duloxetine with concomitant use
of these analgesics was also evaluated.
2.MaterialsandMethods
This was a post hoc analysis of data pooled from two 13-
week, multicenter, randomized, double-blind trials of the
eﬃcacy of duloxetine (doses of 60 QD and 120 QD were
pooled for this analysis) compared with placebo on the
reduction of average pain severity, improvement in physical
function, and in patient global impression of improvement
[11, 12]. Both studies were compliant with International
Conference on Harmonization guidelines on good clinical
practices, and each protocol was approved by the Ethical
Review Board for each site. All patients provided written
informed consent before beginning any study procedures.
Patients included in these studies were outpatients who
were at least 18 years of age with a clinical diagnosis of
CLBP; with pain restricted to the lower back (Class 1) or
associated with radiation to the proximal portion of the
lower limb only (Class 2) according to the Quebec Task
Force (QTF) on Spinal Disorders [13]; with pain present
on most days for ≥6 months, and weekly average pain
severity ratings ≥4 (on a 0–10 numerical scale) during the
week prior to randomization. Exclusion criteria included
clinical or radiographic evidence of radicular compression
or spinal stenosis, presence of spondylolisthesis grade 3–4,
history of ≥1 low-back surgery, any low-back surgery within
12 months, or invasive procedures to reduce low-back pain
within 1 month. Patients with MDD, body mass index >40,
or seeking disability compensation related to back pain were
excluded.
At baseline, patients were stratiﬁed according to con-
comitant NSAID and/or APAP use status prior to study
entryandwererandomizedtoduloxetineandplacebowithin
each stratum. Users were deﬁned as those patients answered
“yes” to a question soliciting whether or not they were
taking a therapeutic dose of NSAID and/or APAP for ≥14
days per month for 3 months immediately preceding the
study. Because the use of these analgesics was recorded as
a global “yes” response, this stratum was referred to as the
NSAID/APAP user group. Patients who were NSAID/APAP
users were allowed to continue with their stable regimen of
NSAID/APAP throughout the entire study.
For this analysis, eﬃcacy measures included the Brief
Pain Inventory (BPI) [14] 24-hour average pain severity item
(referred to hereafter as BPI average pain severity) (range,
0 = no pain to 10 = pain as bad as you can imagine); the
Roland-Morris Disability Questionnaire (RMDQ-24) [15]
(scale range, 0 = no disability to 24 = severe disability); the
PatientGlobalImpressionofImprovement(PGI-I)[16].The
PGI-I is a scale on which patients provide ratings of their
overall impression of how they are feeling since treatment
began with the following range of choices from 1 = very
much better to 4 = no change to 7 = very much worse.
Response to treatment was deﬁned as at least a 50% decrease
from baseline in BPI average pain severity.
To assess and compare the eﬃcacy of duloxetine over
placebo between NSAID/APAP use subgroups, we utilized
an analysis of covariance (ANCOVA) model to estimate
least-squares mean changes from baseline to endpoint in
BPI average pain severity ratings and RMDQ-24 scores. The
ANCOVA model included a ﬁxed continuous covariate of
baseline value, ﬁxed categorical eﬀects of therapy (dulox-
etine or placebo), study, NSAID/APAP use (yes/no), and
therapy-by-NSAID/APAP subgroup interaction. Response at
endpoint was also analyzed using a logistic regression model
with terms for therapy, study, NSAID/APAP use (yes/no),
and therapy-by-NSAID/APAP subgroup interaction. Statis-
tically signiﬁcant diﬀerence in duloxetine eﬃcacy between
subgroups for reduction in BPI average pain severity, im-
provement in RMDQ-24 scores, and BPI pain response
was determined by a therapy-by-NSAID/APAP subgroup
interaction that was P<. 1. The number and proportion of
patients who reached a PGI-I rating of 1 or 2 at endpoint
were summarized by treatment and by NSAID/APAP use
subgroup. Subsequent treatment odds ratios were calculated
f o re a c hs u b g r o u p ,t h e nc o m p a r e db e t w e e ns u b g r o u p sw i t h
the Breslow-Day test, and statistical signiﬁcance was noted
at P<. 1. For patients with missing outcomes (due to early
dropout), the last nonmissing observation was treated as
their endpoint value in the analyses.
Safety assessments included discontinuation due to
adverseevents(AEs),themostcommontreatment-emergent
adverse events (TEAEs), and those possibly related to
NSAID/APAP use (bleeding and cardiovascular events).
Incidence rates were compared between treatment groups
using Cochran-Mantel-Haenszel test controlling for study,
and statistical signiﬁcance was noted at P<. 05.
3. Results
3.1. Patient Disposition. There was no signiﬁcant between-
treatment diﬀerence in rates of study completion in either
NSAID/APAP use subgroup (Table 1). There was a higher
percentage of duloxetine-treated patients versus placebo,
who discontinued due to AEs in the NSAID/APAP nonuser
subgroup (P = .002). For any of the other reasons leading
to discontinuation, there were no signiﬁcant between-treat-
ment diﬀerences in either NSAID/APAP use subgroup.
3.2. Demographics and Clinical Characteristics. Patients were
stratiﬁed according to NSAID/APAP use at baseline: dulox-
etine NSAID/APAP user (n = 137), placebo NSAID/APAPPain Research and Treatment 3
Table 1: Patient disposition.
NSAID/APAP user NSAID/APAP nonuser
Duloxetine
N = 137
n (%)
Placebo
N = 82
n (%)
P value
Duloxetine
N = 206
n (%)
Placebo
N = 156
n (%)
P value
Completed study 90 (65.7) 63 (76.8) .10 136 (66.0) 117 (75.0) .08
Reason for
discontinuation:
Adverse event 21 (15.3) 5 (6.1) .051 39 (18.9) 12 (7.7) .002
Lack of eﬃcacy 7 (5.1) 4 (4.9) 1.00 5 (2.4) 7 (4.5) .38
Lost to follow up 5 (3.6) 0 .16 7 (3.4) 3 (1.9) .53
Protocol violation 5 (3.6) 4 (4.9) .73 5 (2.4) 2 (1.3) .70
Abbreviation: APAP, acetaminophen; NSAID, nonsteroidal anti-inﬂammatory drug.
Table 2: Baseline characteristics.
NSAID/APAP user NSAID/APAP nonuser
Duloxetine
N = 137
Placebo
N = 82
Duloxetine
N = 206
Placebo
N = 156
Age in years, mean (SD) 53.1 (14.7) 51.4 (13.3) 53.5 (14.9) 53.1 (13.6)
Female, n (%) 89 (65.0) 52 (63.4) 114 (55.3) 85 (54.5)
Ethnicity, n (%)
African American 3 (2.2) 3 (3.7) 19 (9.2) 13 (8.3)
Caucasian 108 (78.8) 61 (74.4) 160 (77.7) 123 (78.9)
East Asian 0 0 2 (1.0) 3 (1.9)
Hispanic 25 (18.3) 17 (20.7) 22 (10.7) 15 (9.6)
Native American 0 0 1 (0.5) 2 (1.3)
West Asian 1 (0.7) 1 (1.2) 2 (1.0) 0
CLBP duration since onset,
years, mean (SD) 11.4 (11.5) 9.2 (9.1) 10.8 (11.1) 10.3 (9.0)
QT F class 1, n (%) 94 (72.9) 63 (79.8) 150 (75.4) 99 (68.3)
BPI average pain, mean (SD) 6.1 (1.6) 6.0 (1.6) 5.9 (1.6) 6.1 (1.7)
RMDQ-24, mean (SD) 9.6 (5.0) 8.6 (4.8) 9.1 (4.5) 9.8 (5.3)
TherewasastatisticallysigniﬁcantdiﬀerenceinRMDQ-24scoresbetweentreatmentsinthenonusersubgroup,butthisdiﬀerencewasnotconsideredclinically
signiﬁcant.
Abbreviations: APAP, acetaminophen; BPI, Brief Pain Inventory; CLBP, chronic low back pain; NSAID, nonsteroidal anti-inﬂammatory drugs; QTF, Quebec
Task Force; RMDQ-24, Roland-Morris Disability Questionnaire, SD, standard deviation.
user (n = 82), duloxetine NSAID/APAP nonuser (n =
206), and placebo NSAID/APAP nonuser (n = 156). Patient
demographics and clinical characteristics are summarized
in Table 2. Most of the patients were female, Caucasian,
and in their early ﬁfties. Most had pain restricted to lower
back (Class 1 per QFT on spinal disorders), with an average
duration of CLBP since onset of at least 9 years. At baseline,
the mean BPI average pain severity rating was 6, and the
mean RMDQ-24 rating for physical function was about 9.5.
4. Efﬁcacy
Mean changes from baseline in eﬃcacy measures are shown
in Figures 1 and 2. Treatment-by-NSAID/APAP use sub-
group interactions were not signiﬁcant for reduction n BPI
averagepainseverity(P = .31,Figure 1),orforimprovement
in physical function assessed by the RMDQ-24 (P = .35,
Figure 2). These results suggest that there was no substantial
evidence of diﬀerential duloxetine eﬃcacy on pain reduction
or improvement in physical function between concomitant
NSAID/APAP users and nonusers. The frequency of PGI-
I responses that were “much better” or “very much better”
(PGI-I endpoint score ≤2) is presented in Figure 3.I n
both NSAID/APAP use subgroups, a higher percentage of
duloxetine-treated patients achieved PGI-I ≤2 at endpoint,
but the treatment odds ratios were not signiﬁcantly diﬀerent
betweenthetwosubgroups(P = 0.32).Therefore,signiﬁcant
diﬀerential treatment eﬀects of duloxetine on PGI-I were
not observed between concomitant NSAID/APAP users and
nonusers.
The criterion for achieving a pain response was met by
a higher percentage of duloxetine-treated patients in both
NSAID/APAP use subgroups (46.2% of users, and 43.6% of
nonusers)thanpatientstreatedwithplacebo(38.0%ofusers,4 Pain Research and Treatment
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Figure 1: Estimated least-squares (LS) mean changes from baseline
and standard errors in BPI average pain severity in patients who
concomitantly used or did not use NSAID or APAP.
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Figure 2: Estimated least-squares (LS) mean changes from baseline
andstandarderrorsinRMDQratinginpatientswhoconcomitantly
used or did not use NSAID or APAP.
and 27.5% of nonusers). The treatment-by-NSAID/APAP
use subgroup interaction was not signiﬁcant (P = 0.28),
which suggests that the duloxetine treatment eﬀects on
achieving a pain response were not statistically signiﬁcantly
diﬀerent between concomitant NSAID/APAP users and
nonusers.
5.Safety
The most common AEs that lead to discontinuation in the
NSAID/APAP use subgroup in duloxetine- treated patients
were erectile dysfunction and nausea (both events, n = 2,
1.5%); events in the nonuser subgroup included nausea,
insomnia and somnolence (each event, n = 3, 1.5%).
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Figure 3: Percentage of patients who felt “much better” or “very
much better” at endpoint.
TEAEswithinNSAID/APAPusesubgroupsthatoccurred
at a rate of at least 5% with duloxetine treatment and were
signiﬁcantly more frequent than with placebo are summa-
rized in Table 3. Among NSAID/APAP users, the frequency
of nausea, dry mouth, constipation, somnolence, and fatigue
were signiﬁcantly greater in patients who received duloxetine
versus placebo. In addition to these TEAEs, insomnia, and
dizziness were signiﬁcantly more frequent in patients who
received duloxetine versus placebo among the NSAID/APAP
nonusers. Cardiovascular and bleeding-related TEAEs are
summarized in Table 4. In either NSAID/APAP use sub-
group, between-treatment diﬀerences in the frequency of
these events were not signiﬁcant.
6. Discussion
There are few published CLBP studies with nonopioid
analgesics that allowed concomitant NSAID/APAP use. Two
studies investigated the eﬃcacy of TCAs for pain reduction
in patients who were allowed to continue taking NSAIDS.
One of those two evaluated nortriptyline against placebo
[17] and the other compared maprotiline with paroxetine
[18], but neither study reported eﬃcacy outcome compar-
isons between NSAID/APAP users and nonusers. Another
CLBP study examined the eﬃcacy of pregabalin combined
with celecoxib, and the results suggested that combination
treatment was more eﬃcacious than treatment with either
medication alone [19].
The post hoc analysis reported here included two clinical
trials of duloxetine that allowed concomitant NSAID/APAP
for those patients who regularly used them prior to study
entry. The use of additional analgesics in a pain trial is
associated with the risk of reduced assay sensitivity, and
possibly a high placebo response [17]. This was observed
in one of the two duloxetine CLBP trials [12] and in the
NSAID/APAP use subgroup in this analysis. However, the
treatment-by-NSAID/APAP use subgroup interaction was
not signiﬁcant in the analyses of various eﬃcacy measures,
which suggests that the advantages of duloxetine over
placeboinpainreductionandimprovementinfunctionwere
not signiﬁcantly diﬀerent between subgroups.Pain Research and Treatment 5
Table 3: Treatment-emergent adverse events within either NSAID/APAP use subgroups that occurred at a rate of at least 5% with duloxetine
treatment and were signiﬁcantly more frequent than with placebo.
NSAID/APAP User NSAID/APAP Nonuser
Duloxetine
N = 137
n (%)
Placebo
N = 82
n (%)
P value
Duloxetine
N = 206
n (%)
Placebo
N = 156
n (%)
P value
At least 1 adverse
event 92 (67.2) 51 (62.2) .850 141 (68.5) 77 (49.4) <.001
Nausea 25 (18.3) 3 (3.7) .006 26 (12.6) 4 (2.6) <.001
Dry mouth 14 (10.2) 1 (1.2) .018 21 (10.2) 4 (2.6) .004
Constipation 13 (9.5) 1 (1.2) .041 17 (8.3) 1 (0.6) .001
Somnolence 13 (9.5) 0 .006 12 (5.8) 1 (0.6) .012
Fatigue 10 (7.3) 0 .012 15 (7.3) 1 (0.6) .003
Insomnia 13 (9.5) 4 (4.9) .346 23 (11.2) 4 (2.6) .004
Dizziness 10 (7.3) 2 (2.4) .197 15 (7.3) 3 (1.9) .023
P values from Cochran-Mantel-Haenszel test.
Abbreviation: APAP, acetaminophen; NSAID, nonsteroidal anti-inﬂammatory drugs.
Table 4: Bleeding-related or cardiac-related treatment-emergent adverse events.
NSAID/APAP user NSAID/APAP nonuser
Duloxetine
N = 137
n (%)
Placebo
N = 82
n (%)
P value
Duloxetine
N = 206
n (%)
Placebo
N = 156
n (%)
P value
Bleeding-related
Tendency to bruise 1 (0.7) 0 .52 0 0 —
Eye hemorrhage 0 0 — 1 (0.5) 1 (0.6) .70
Hemorrhagic cyst 0 0 — 1 (0.5) 0 .31
Rectal hemorrhage 0 0 — 1 (0.5) 0 .44
Cardiac-related
Palpitations 5 (3.7) 0 .14 1 (0.5) 1 (0.6) .86
Hypertension 3 (2.2) 1 (1.2) .84 4 (1.9) 2 (1.3) .76
Myocardial
infarction 1 (0.7) 0 .52 0 1 (0.6) .32
Tachycardia 1 (0.7) 0 .29 2 (1.0) 0 .15
Transient ischemic
attack 1 (0.7) 0 .52 1 (0.5) 0 .31
Heart rate
increased 0 0 — 1 (0.5) 0 .44
Hypertensive crisis 0 0 — 1 (0.5) 0 .44
Carotid artery
stenosis 1 (0.7) 0 .52 0 0 —
Abbreviation: APAP, acetaminophen; NSAID, nonsteroidal anti-inﬂammatory drugs.
The safety proﬁle with regards to TEAEs in either
NSAID/APAP use subgroup did not diﬀer from those re-
ported previously in duloxetine trials. Although the occur-
rence of bleeding-related and cardiac-related events noted
in this post hoc analysis was low in both NSAID/APAP
use group, caution is warranted for concomitant use of
NSAID/APAP withduloxetine. Thisprecautionary statement
is based upon observations that medications that act to
inhibit serotonin reuptake may be associated with an in-
creased risk of bleeding events [9], and the use of these drugs
in combination with medications that aﬀect coagulation,
including NSAIDs, may increase this risk.
This study is limited by the lack of complete information
regarding dosing and frequency of concomitant NSAID or
APAP use. In addition, any NSAID or APAP use less than
14 days/month would have classiﬁed patients as nonusers,
which also included patients that did not use these analgesics
at all, and patients who used them sporadically. In addition,
users were identiﬁed at baseline by responding “yes” to a
questionnaire regarding the use of either NSAIDs or APAP,6 Pain Research and Treatment
instead of regarding the use of one or the other or both, so
this lack of information limited further analysis. Also, the
studies included in these analyses were not powered to detect
diﬀerential treatment eﬀect between NSAID/APAP use sub-
groups. Therefore, the comparisons between NSAID/APAP
use subgroups in this study should be viewed in that light.
In addition, the sample size and the short duration of the
studies also limited the occurrence and detection of rare
bleeding events. Finally, these studies excluded individuals
with certain comorbidities, so these results may not extend
to all individuals in the general population who present with
CLBP.
7. Conclusions
In this post hoc analysis of data pooled from two studies
in patients with CLBP, there were no statistically signiﬁcant
diﬀerences in the treatment advantage of duloxetine over
placebo on measures of pain reduction, improved physical
function, or patient global impression of improvement
observed between concomitant NSAID/APAP users and
nonusers. In other words, concomitant use of an NSAID
or APAP did not signiﬁcantly enhance or interfere with the
eﬃcacy of duloxetine. The safety of duloxetine with con-
comitant NSAID/APAP use was consistent with the known
duloxetine safety and tolerability proﬁle.
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